Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.
| Revenue (TTM) | $293.63M |
| Gross Profit (TTM) | $83.75M |
| EBITDA | $-26.11M |
| Operating Margin | -21.70% |
| Return on Equity | -39.50% |
| Return on Assets | -3.92% |
| Revenue/Share (TTM) | $0.82 |
| Book Value | $1.17 |
| Price-to-Book | 0.86 |
| Price-to-Sales (TTM) | 1.53 |
| EV/Revenue | 1.782 |
| EV/EBITDA | 11014.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $422.15M |
| Float | $422.23M |
| % Insiders | 0.19% |
| % Institutions | 7.92% |
Volatility is currently expanding
Canadian cannabis stocks are once again gaining attention as investors search for opportunities within the global marijuana industry. The sector has experienced significant changes since Canada legalized recreational cannabis in 2018. However, several leading companies have emerged stronger after years of restructuring, cost reductions, and increased competition.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the Company has mailed (or mailed a notice of internet availability with respect to) its proxy statement and fiscal 2026 annual report to shareholders (collectively, the “Meeting Materials”) for its Annual General and Special Meeting of shareholders (the “Meeting”) sche.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that its Kincardine, Ontario cultivation facility (“Kincardine”) has received renewed European Union Good Manufacturing Practice (“EU GMP”) certification from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg. With its EU GMP status.
Curaleaf recently announced plans for a takeover of Aurora Cannabis, a rival of Canopy Growth. Canopy Growth is an iconic cannabis company in Canada with a strong position in the market.
Canopy Growth NASDAQ: CGC is positioning itself for further expansion in medical cannabis, European markets and Canadian recreational cannabis after restructuring operations, reducing costs and acquiring MTL Cannabis, President and CEO Luc Mongeau said during a Canaccord Genuity presentation.
Canopy Growth NASDAQ: CGC reported first-quarter fiscal 2027 net revenue of C$81.2 million, up 13% from the prior-year period, as the company recorded year-over-year growth across its cannabis and Storz & Bickel businesses.
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported continued revenue growth across its businesses in the first quarter of fiscal 2027, while the cannabis company narrowed its adjusted EBITDA loss from a year earlier, sending its shares 5% higher on Friday morning. Net revenue for the three months ended June 30, 2026, increased 13% year-over-year to C$81.2 million, exceeding the analyst consensus estimate of C$58.89 million.
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth to report Q1 2027 financial results on August 7 with a conference call at 10:00am ET.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CGC and any ticker you trade — then tracks every position and per-strategy win rate.
